http://groups.yahoo.com/group/aspartameNM/message/1011
excitotoxicity autism disorders: Russell L. Blaylock, MD: Part 2/2,
References: Murray 7.10.3 rmforall

www.dorway.com/blayautism.txt: excitotoxicity disorders, References:
Russell L. Blaylock, MD: Part 2/2: Murray 7.10.3 rmforall
http://groups.yahoo.com/group/aspartameNM/message/1011

www.dorway.com/blayautism.txt
The Central Role of Excitotoxicity in Autism Spectrum Disorders
Russell L. Blaylock, MD

References to Part 1/2
http://groups.yahoo.com/group/aspartameNM/message/1010

1.
Lipton SA, Rosenberg PA. Excitatory amino acids as a final common
pathway for neurological disorders. N Eng J Med 330: 613-622, 1994.
2.
Olney JW. Brain lesions, obesity, and other disturbances in mice treated
with monosodium glutamate. Sci 165: 719-721, 1969.
3.
Gasic GP, Heinemann S. Receptors coupled to ionic channels: the
glutamate receptor family. Curr Opinion Neurobiol 1: 20-26, 1991.
4.
Seal RP, Amara SG. Excitatory amino acid transporters: a family in flux.
Ann rev Pharmacol Toxicol 39: 431-456, 1999.
5.
Bolanos JP, Aleida A, Stewart V, et al. Nitric oxide-mediated
mitochondrial damage in the brain: mechanisms and implications for
neurodegenerative diseases. J Neurochem 68: 2227-2240, 1997.
6.
O’Banion MK. Cyclooxygenase-2: molecular biology, pharmacology, and
neurobiology. Critical Rev Neurobiol 13: 45-82, 1999.
7.
Kruman I, Bruce-Keller AJ, Bredesen D, et al. Evidence that 4-
hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J
Neurosci 17: 5089-5100, 1997.
8.
Mattson MP, Fu W, Waeg G, Uchida K. 4-hydroxynonenal, a product of lipid
peroxidation, inhibits dephosphorylation of the microtubule-associated
protein tau. Neuroreport 8: 2275-2281, 1997.
9.
Vander Jagt DL, Hunsaker LA, vander Jagt TJ, et al. Inactivation of
glutathione reductase by 4-hydroxynonenal and other endogenous
aldehydes. Biochem Pharmacol 53: 1133-1140, 1997.
10.
Grune T, Michel P, Eggbert W, et al. Increased levels of 4-
hydroxynonenal modified proteins in plasma of children with autoimmune
diseases. Free Rad Biol Med 23: 357-360, 1997.
11.
Foley TD. The lipid peroxidation product 4-hydroxynonenal potently and
selectively inhibits synaptic plasma membrane ecto-ATPase activity, a
punitive regulator of synaptic ATP and adenosine. Neurochem Res 24:
1241-1248, 1999.
12.
Henneberry RC. The role of neuronal energy in neurotoxicity of
excitatory amino acids. Neurobiol Aging 10: 611-613, 1989.
13.
Eliasson MJ, Huang Z, Ferrante RJ. Neuronal nitric oxide synthease
activation and peroxynitrite formation in ischemic stroke linked to
neural damage. J Neurosci 19: 5910-5918, 1999.
14.
Rapin I, Autistic regression and disintegrative disorder: how important
the role of epilepsy. Semin Pediatr Neurol 2: 278-285, 1995.
15.
Tuchman RF, Rapin I. Regression in pervasive developmental disorders:
seizures and epileptiform electroencephalogram correlates. Pediatrics
99: 560-566, 1997.
16.
Childs JA and Blair JL. Valproic acid treatment of epilepsy in autistic
twins. J Neurosci Nurs 29: 244-248, 1997.
17.
Smalley L. Autism and tuberous sclerosis. J Autism Dev Disord 28: 407-
414, 1998.
18.
Lewine JD, Andrews R, Chez M, et al. Magnetoencephalographic patterns of
epileptiform activity in children with regressive autism spectrum
disorders. Pediatrics 104: 405-418, 1999.
19.
Baumeister FA, Gsell W, Shin YS, Egger J. Glutamate in pyridoxine-
dependent epilepsy: neurotoxic glutamate concentration in the
cerebrospinal fluid and its normalization by pyridoxine. Pediatrics 94:
318-321, 1994.
20.
Burd L, Stenehjem A, Franceschini LA, Kerbeshfan J. A 15 year follow-up
of a boy with pyridoxine ( vitamin B6)-dependent seizures with autism,
breath holding, and severe mental retardation. J Child Neurol 15: 763-
765, 2000.
21.
Chou ML, Wang HS, Hung PC, et al. Late-onset pyridoxine-dependent
seizures: report of two cases. Zhonghua Min Guo Xiao Ke Yi Xue Hui Za
Zhi 36: 434-437, 1995.
22.
Baxter P, Griffiths P, Kelly T, Gardner-Medwin D. Pyridoxine-dependent
seizures: demographic, clinical MRI and psychometric features, and
effect of dose on intelligence quotient. Dev Med Child Neurol. 38: 998-
1006, 1996.
23.
Gospe SM, Hecht ST. Longitudinal MRI findings in pyridoxine-dependent
seizures. Neurology 51: 74-78, 1998.
24.
Mathern GW, Pretorius JK, Mendoza D, et al. Hippocampal N-methyl-D-
aspartate receptor subunit mRNA levels in temporal lobe epilepsy
patients. Ann Neurol 46: 343-358, 1999.
25.
Isokawa M, Levesque MF. Increased NMDA responses and dendritic
degeneration in human epileptic hippocampal neurons in slices. Neurosci
Lett 132: 212-216, 1991.
26.
Saitoh O, Karns CM, Courchesne E. Development of the hippocampal
formation from 2 to 42 years: MRI evidence of smaller area dentata in
autism. Brain 124: 1317-1324, 2001.
27.
Kikuchi M, Kashii S, Honda Y, et al. Protective action of zinc against
glutamate neurotoxicity in cultured retinal neurons. Invest Opthalmol
Vis Sci 36: 2048-2053, 1995.
28.
Kasarskis EJ, Forrester TM, Slevin JT. Hippocampal zinc during amygdalar
kindling in the rat. Epilepsia 26: 513-18, 1985.
29.
Rogawski MA. Excitatory Amino Acids and Seizures. In, Stone TW ( Ed),
CNS Neurotransmitters and Neuromodulators: Glutamate. CRC Press, Boca
Raton, pp 219-237, 1995.
30.
Ekonomou A, Angelatou F. Upregulation of NMDA receptors in hippocampus
and cortex in the pentylenetetrazol-induced “kindling” model of
epilepsy. Neurochem Res 24: 1515-1522, 1999.
31.
Olney JW, Collias RC, Sloviter RS. Excitotoxic mechanism of epileptic
brain damage. Adv Neurol 44: 857-877, 1986.
32.
Khanna N, Bhalla S. Role of ketamine in convulsions. Indian J Med Sci
53: 475-480, 1999, and Sheth RD, Gidal BE. Refractory status
epilepticus: response to ketamine. Neurology 51: 1765-1766, 1998.
33.
Ben-Ari Y. Limbic seizure and brain damage produced by kainic acid:
mechanisms and relevance to human temporal lobe epilepsy. Neuroscience
14: 375-403, 1985.
34.
Vezzani A, Serafini R, Stasi Ma, et al. Kinetics of MK-801 and its
effects on quinolinic acid-induced seizures and neurotoxicity in rats. J
Pharmacol Exp Ther 249: 278-283, 1989.
35.
Rego AC, Santos MS, Oliveira CR. Glutamate-mediated inhibition of
oxidative phosphorylation in cultured retinal cells. Neurochem Int 36:
159-166, 2000.
36.
Newell DW, Barth A, Ricciardi TN, Malouf AT. Glycine causes increased
excitability and neurotoxicity by activation of NMDA receptors in the
hippocampus. Exp Neurol 145: 235-244, 1997.
37.
Cotterell KL, Croucher MJ, Bradford HF. Weak anticonvulsant activity of
GGP 37849 and GGP 39551 against kindled seizures following systemic
administration. Eur J Pharmacol 214: 285-287,1992.
38.
Swann JW, Hablitz JJ. Cellular abnormalities and synaptic plasticity in
seizure disorders of the immature nervous system. Ment Retard Dev
Disabil Res 6: 258-267, 2000.
39.
Johnston MV. Neurotransmitters and vulnerability of the developing
brain. Brain Dev 17: 301-306. 1995.
40.
Mrak RE, Sheng JG, Griffin ST. Glial cytokines in Alzheimer’s disease.
Human Pathol 26: 816-823, 1995.
41.
Lin HC, Wan FJ, Wu CC, Tseng CJ. Systemic administration of
lipopolysaccride induces release of nitric oxide and glutamate and c-fos
expression in the nucleus tractus solitarii of rats. Hypertension 33:
1218-1224, 1999.
42.
Saito K, Crowley JS, Markey SP, Heyes MP. A mechanism for increased
quinolinic acid formation following acute systemic stimulation. J Biol
Chem 268: 15496-15503, 1993.
43.
Banati RB, Gehrmann J, Schubert P, et al. Cytotoxicity of microglia.
Glia 7: 111-118, 1993.
44.
Leslie JB, Watkins D. Eicosanoids in the central nervous system. J
Neurosurgery 63: 659-668, 1985.
45.
Pellegrini-Giampietro DE, Cherici G, Alesiani M, et al. Excitatory amino
acid release from rat hippocampal slices as a consequence of free
radical formation. J Neurochem 51: 1960-1963, 1988.
46.
Saito K, Markey SP, Heyes MP. Effects of immune activation on quinolinic
acid and neuroactive kyurenines in the mouse. Neuroscience 51: 25-39,
1992.
47.
Fontana A, Constam D, Frei K, et al. Cytokines and defense Against CNS
Infection, In, Ransohoff RM, Beneviste EN (Eds), Cytokines and the CNS.
CRC Press, Baca Raton, 188-220, 1996.
48.
Piani D and Fontana A. Involvement of the cystine transport system xc in
the macrophage induced glutamate dependent cytotoxicity to neurons. J
Immunol 152: 3578-3585, 1994.
49.
Komuro H, Rakic P. Modulation of neuronal migration by NMDA receptors.
Science 260: 95-97, 1993.
50.
Heyes MP, Achim CL, Major EO, et al. Human microglia convert L-
tryptophan into the neurotoxin quinolinic acid. Biochem J 320: 595-597,
1996.
51.
Ascher M, Du YL, Gannon M, Kimelberg HK. Methylmercury-induced
alterations in excitatory amino acid transport in rat primary astrocyte
cultures. Brain Res 602: 181-186, 1993.
52.
Blanc EM, Keller JN, Fernandez S, Mattson MP. 4-hydroxynonenal, a lipid
peroxidation product, impairs glutamate transport in cortical
astrocytes. Glia 22: 149-160, 1998.
53.
Trotti D, Danbolt NC, Volterra A. Glutamate transporters are oxidant-
vulnerable: a molecular link between oxidative and excitotoxic
neurodegeneration? Trens Pharm Sci 19: 328-334, 1998.
54.
Li S, Mallory M, Alford M, et al. Glutamate transporter alterations in
Alzheimer’s disease are possibly associated with abnormal APP
expression. J Neuropath Exp Neurol 56: 901-911, 1997.
55.
Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the
brain and spinal cord in amyotrophic lateral sclerosis. New Eng J Med
326: 1464-1468, 1992.
56.
Aschner M, Gannon M, Kimelberg HK. Methylmercury-induced alterations in
excitatory amino acid transport in rat primary astrocyte cultures. Brain
Res 602: 181-186, 1993.
57.
Hultman P, Lindh U, Horsted-Bindslev P. Activation of the immune system
and syetemic immune-complex deposits in Brown Norway rats with dental
amalgam restorations. J Dental Res 77: 1415-1425, 1998.
58.
Hultman P, Lindh U, Horsted-Bindslev P. Activation of the immune system
and syetemic immune-complex deposits in Brown Norway rats with dental
amalgam restorations. J Dental Res 77: 1415-1425, 1998.
59.
Michel P, Eggert W, Albrecht -Nebe H, Grune T. Increased lipid
peroxidation in children with autoimmune diseases. Acta Paediatr 86:
609-612, 1997.
60.
Mogi M, Harada M, Narabayashi H, Inagaki H, et al. Interleukin ( IL) -
1ß, IL-2, IL-6, and transforming growth factor-alpha levels are elevated
in ventricular spinal fluid of juvenile parkinsonism and Parkinson’s
disease. Neurosci Lett 211: 13-16, 1995.
61.
Alexianu ME. The role of immune processes in amyotrophic lateral
sclerosis pathogenesis. Rom J Neurol Psychiatry 33: 215-227, 1995.
62.
Popovic M, Caballero-Bleda M, Puelles L, Popovic N. Importance of
immunological and inflammatory processes in the pathogenesis and therapy
of Alzheimer’s disease. Intern J Neurosci 95: 203-236, 1998.
63.
Nakagawa K, Harrison LC. The potential roles of endogenous retroviruses
in autoimmunity. Immunol rev 152: 193-236, 1996.
64.
Jahnke U, et al. Sequence homology between certain viral proteins and
proteins related to encephalomyelitis and neuritis. Science 29: 282-284,
1985.
65.
Eastman CL, Urbanska E, Love A, et al. Increased brain quinolinic acid
production in mice infected with a hamster neurotropic measles virus.
Exp Neurol 125: 119-124, 1994.
66.
Anderson T, Schultzberg M, Schwartz R, et al. NMDA-receptor antagonist
prevents measles virus-induced neurodegeneration. Eur J. Neurosci 3: 66-
69, 1990.
67.
Martinon-Torres F, Magarinos MM, Picon M, et al. Self-limited acute
encephalopathy related to measles component of viral triple vaccine. Rev
Neurol 28: 881-882, 1999.
68.
Andersson T, Schwartz R, Love A, Kristensson K. Measles virus-induced
hippocampal neurodegeneration in the mouse: a novel, subacute model for
testing neuroprotective agents. Neurosci Lett 154: 109-112, 1993.
69.
Alves RS, Barbosa ER, Scaff M. Postvaccinal parkinsonism. Mov Disord 7:
178-180, 1992.
70.
Klockgether T, Turski L. Toward an understanding of the role of
glutamate in experimental parkinsonism: agonist -sensitive sites in the
basal ganglion. Ann Neurol 34: 585-593, 1993.
71.
Zhang J, price JO, Graham DG, Montine TJ. Secondary excitotoxicity
contributes to dopamine-induced apoptosis of dopaminergic neuronal
cultures. Biochem Biophys Res Commun 248: 812-816, 1998.
72.
Sonsalla PK, Nicklas WJ, Heikkila RE. Role for excitatory amino acids in
methamphetamine-induced nigrostriatal dopaminergic toxicity. Science
243: 398-400, 1989.
73.
Liebert UG, Hashim GA, ter Meulen V. Characterization of measles virus-
induced cellular autoimmune reactions against myelin basic protein in
Lewis rats. J Neuroimmunol 29: 139-147, 1990.
74.
Racke MK, Burnett D, Pak SH, et al .Retinoid treatment of experimental
allergic encephalomyelitis, IL-4 production correlates with improved
disease course. J Immunol 154: 450-458, 1995.
75.
Kelly D, Coutts AG. Early nutrition and the development of immune
function in the neonate. Proc Nutr Soc 59: 177-185, 2000.
76.
Kato K, Hamada N, et al. Depression of delayed-type hypersensitivity in
mice with hypothalamic lesions induced by monosodium glutamate:
involvement of neuroendocrine system in immunomodulation. Immunology 58:
389-395, 1986.
77.
Frederickson CJ, Dancher G. Hippocampal Zinc, the Storage Granule Pool:
Localization, Physiochemistry, and Possible Functions, In, Morley JE,
Sterman MB, Walsh JH ( Eds), Nutritional Modulation of Neural Function.
Academic Press, San Diego, 289-306, 1988.
78.
Westbrook GL, Mayer ML. Micromolar concentrations of ZN +2 antagonize
NMDA and GABA responses of hippocampal neurons. Nature 328: 640-643,
1987.
79.
Cuajungco MP, Lees GJ. Zinc metabolism in the brain: relevance to human
neurodegenerative disorders. Neurobiol Dis 4: 137-169, 1997.
80.
Yazdani M, Fontenot F, Gottschalk SB, et al. Relationship of prenatal
caffeine exposure and zinc supplementation on fetal rat brain growth.
Dev Pharmacol Ther 18: 108-115, 1992.
81.
Dickens BF, Weglicki WB, Li Y-S, Mak IT. Magnesium deficiency in vitro
enhances free radical-induced intracellular oxidation and cytotoxicity
in endothelial cells. Fed Euro Biochem Soc 311: 187-191, 1992.
82.
Wolf G, Keilhoff G, Fisher S, Hass P. Subcutaneously applied magnesium
protects reliably against quinolinate-induced N-methyl-D aspartate
(NMDA)-mediated neurodegeneration and convulsions in rats: are there
therapeutical implications? Neuroscience Lett 117: 207-211, 1990.
83.
Goto I, Nagara H, Tateishi J, Kuroiwa Y. Thiamine-deficient
encephalopathy in rats: effects of deficiencies of thiamine and
magnesium. Brain Res 372: 31-36, 1986.
84.
El-Beheiry H and Puil E. Effects of hypomagnesia on transmitter actions
in neocortical slices. Br. J Pharmacol 101: 1006-1010, 1990.
85.
Issaadeh S, Ljungdahl A, Hojeberg B, et al. Cytokine production in the
central nervous system of Lewis rats with experimental autoimmune
encephalomyelitis: dynamics of mRNA expression for interlekin-10,
interleukin-12, cytolysin, tumor necrosis factor alpha and tumor
necrosis factor beta. J Neuroimmunol 61: 205-212, 1995.
86.
Jarskog LF, Xiao H, Wilkie MB, et al. Cytokine regulation of embryonic
rat dopamine and serotonin neuronal survival in vitro. In J Dev Neurosci
15: 711-716, 1997.
87.
Petitto JM, McNamara RK, Gendreau Pl, et al. Impaired learning and
memory and altered hippocampal neurodevelopment resulting from
interleukin-2 gene deletion. J Neurosci Res 56: 441-446, 1999.
88.
Brenneman DE, Schultzberg M, Bartfai T, Gozes I. Cytokine regulation of
neuronal survival. J Neurochem 58: 454-460, 1992.
89.
Jarskog LF, Xiao H, Wilkie MB, et al. Cytokine regulation of embryonic
rat dopamine and serotonin neuronal survival in vitro. In J Dev Neurosci
15: 711-716, 1997.
90.
Downen M, Amaral TD, Hua LL, Zhao ML, Lee SC. Neuronal death in
cytokine-activated primary human brain cell culture: role of tumor
necrosis factor-alpha. Glia 28: 114-127, 1999.
91.
Fosslier E. Mitochondrial medicine-molecular pathology of defective
oxidative phosphorylation. Ann Clin Lab Sci 31: 25-67, 2001.
92.
Turowski RC, Triozzi PL. Central Nrevous System Toxicities of Cytokine
Therapy, In, Plotnikoff NP, Faith RE, et al, (Eds), Cytokines: Stress
and Immunity. CRC Press Boca Raton, 1998, 97-103.
93.
Meyers CA, Valentine AD, Wong FCL, Leeds NE. Reversible neurotoxicity of
interleukin-2 and tumor necrosis factor: correlation of SPECT with
neuropsychological testing. J Neuropsychiatr Clin Neurosci 6: 285-288,
1994.
94.
Renault PF, Hoofnagle JH, Mullen KD, et al. Psychiatric complications
of longed term interferon-alpha therapy. Arch Intern Med 147: 1577-
1580, 1987.
95.
Thompson JA, Lee DJ, Lindgren CG, et al. Influence of dose and duration
of infusion of interleukin-2 on toxicity and immunomodulation. J Clin
Oncol 6: 669- 678, 1988.
96.
Curti BD, Smith JW,II. Interleukin-1 in the treatment of cancer.
Pharmacol Ther 65: 291-202, 1995.
97.
Calvet MC, Gresser I. Interferon enhances the excitability of cultured
neurons. Nature 278: 558-560, 1979.
98.
Jong AY, Stins MF, Huang SH, et al. Traversal of Candida albicans across
human blood-brain barrier in vitro. Infect Immun 69: 4536-4544, 2001.
99.
Urnovitz HB, Murphy WH. Human endogenous retroviruses: nature,
occurrence, and clinical implications in human disease. Clinical
Microbiology Reviews 9: 72-99, 1996.
100.
Matsuzono Y, Narita M, Satake A, et al. Measles encephalomyelitis in a
patient with a history of vaccination. Acta Paediatr Jpn 37: 374-376,
1995.
101.
Olney JW, Farber NB, Wozniak DF, et al. Environmental agents that have
the potential to trigger massive apoptotic neurodegeneration in the
developing brain. Environ Health Perspect 108: 383-388, 2000.
102.
Guilarte TR. The N-Methyl-D-Aspartate Receptor: Physiology and
Neurotoxicology in the Developing Brain. In, Slikker W, Chang DW (Eds),
Handbook of Developmental Neurotoxicology. Academic Press, San Diego,
285-304, 1998
103.
Piani D, Fontana A. Involvement of the cystine transport system xc- in
the macrophage-induced glutamate-dependent cytotoxicity to neurons. J
Immunol 152: 3578-3585, 1994.
104.
Janaky R, Ogita K, Pasqualotto BA, et al. Glutathione and signal
transduction in mammalian CNS. J Neurochem 73: 889-902, 1999.
105.
Levy DI, Sucher NJ, Lipton SA. Glutathione prevents N-methyl-D aspartate
receptor-mediated neurotoxicity. Neuroreport 2: 345-347, 1991.
106.
Holmes GL, Ben-Ari Y. The neurobiology and consequences of epilepsy in
the developing brain. Pediatr Res 49: 320-325, 2001.
107.
Villeneuve N, Ben-Ari Y, Holmes GL, Gaiarsa JL. Neonatal seizures
induced persistent changes in intrinsic properties of CA1 rat
hippocampal cells. Ann Neurol 47: 729-738, 2000.
108.
Szasz A, Bavana B, et al. Chronic low-dose maternal exposure to
methylmercury enhances epileptogenecity in developing rats. In J Dev
Neurosci 17: 733-742, 1999.
109.
Koenig H, trout JJ, Glodstone, Lu CY. Capillary NMDA receptors regulate
blood-brain barrier and breakdown. Brain Res 588: 297-303, 1992.
110.
Lagrange P, Romero IA, Minn A, Revest PA. Transendothelial permeability
changes induced by free radicals in an in vitro model of the blood-brain
barrier. Free Rad Biol Med 27: 667-672, 1999.
111.
Gupta A, Agarwal R, Shukla GS. Functional impairment of blood-brain
barrier following pesticide exposure during early development in rats.
Hum Exp Toxicol 18: 174-179, 1999.
112.
Bolton C, Paul C. MK-801 limits neurovascular dysfunction during
experimental allergic encephalomyelitis.Pharm Exp Ther 282: 397-402,
1997.
113.
Olney JW. Excitotoxic food additives: functional teratological aspects.
Prog Brain Res 18: 283-294, 1988.
114.
Olney JW Glutamate: a neurotoxic transmitter. J Child Neurol 4:218-226,
1989.
115.
Morrisett RA, Mott DD, Lewis DV, et al. Reduced sensitivity of the N-
methyl-D-aspartate component of synaptic transmission to magnesium in
hippocampal slices from immature rats. Dev Brain Res 56: 257-262, 1990.
116.
Blaylock RL. Food additive excitotoxins and degenerative brain
disorders. Medical Sentinel 4: 212-215, 1999.
117.
Shaw W. Biological Treatments for Autism and PDD, Great Plains
Laboratory, 53, 1998.
118.
Kaneda K, Kikuchi M, Kashii S, et al. Effects of B vitamins on
glutamate-induced neurotoxicity in retinal cultures. Eur J Pharmacol
322: 258-264, 1997.
119.
Akaike A, Tamura Y, Sato Y, Yokota T. Protective effects of a vitamin
B12 analog, methylcobalamin, against glutamate cytotoxicity in cultured
cortical neurons. Eur J Pharmacol 241: 1-6, 1993.
120.
Rimland B. The Use of Vitamin B6, Magnesium, and DMG in the Treatment of
Autistic Children and Adults. In, Shaw W, (Ed), Biological Treatments
for Autism and PDD. Great Plains Laboratory, 176-195, 1998.
121.
Ruiz F, Alvarez G, Pereira R, Hernandez M, et al. Protection by pyruvate
and malate against glutamate-mediated neurotoxicity. Neuroreport 9:
1277-1282, 1998.
122.
Blaylock R Phytonutrients and metabolic stimulants as protection against
neurodegeneration and excitotoxicity. JANA 2: 30- 39, 2000.
123.
Saari MJ, Fong S, Shrivji A, Armstrong JN. Enriched housing mask
deficits in place navigation induced by neonatal monosodium glutamate.
Neurotoxicol Teratol 12: 29-32, 1990.
************************************************************************

http://groups.yahoo.com/group/aspartameNM/message/97
Lancet website aspartame letter 7.29.99:
Excitotoxins 1999 Part 1/3 Blaylock: Murray 1.14.0 rmforall
The Medical Sentinel Journal 1999 Fall; (95 references)

Russell L. Blaylock, MD 601-982-1175 Madison, Mississippi
http://www.bioterrorismbook.com/ "Bioterrorism: How You Can Survive"
Advanced Nutritional Concepts,LLC PO Box 2670 Ridgeland, MS 39158-2670
http://www.dorway.com/blayenn.html
"Excitotoxins: The Taste that Kills", 1977, 298 p., 493 references.
"Health and Nutrition Secrets that can save your life", 2002, 459 p.,
558 + 30 references, $ 30 http://www.healthpress.com/
goodbooks@... PO Box 37470 Albuquerque, NM 87176
505-888-1394 fax 505-888-1521 Kathleen Frazier, Publisher

George R. Schwartz, MD "In Bad Taste: The MSG Syndrome", 1988, 123 p.

http://www.truthinlabeling.org/ Truth in Labeling Campaign [MSG]
Adrienne Samuels, PhD The toxicity/safety of processed
free glutamic acid (MSG): a study in suppression of information.
Accountability in Research 1999; 6: 259-310. 52-page review
P.O. Box 2532 Darien, Illinois 60561
858-481-9333 adandjack@...

http://www.msgmyth.com/ Debby Anglesey <avenger@...>
Battling the "MSG Myth", A Survival Guide and Cookbook - $19.00
P.O. Box 895 Richland, WA 99352 509-735-3397
************************************************************************

http://groups.yahoo.com/group/aspartameNM/message/1002
http://groups.yahoo.com/group/aspartame/message/15477
aspartame review: methanol, formaldehyde, formic acid toxicity:
Murray 7.10.3 rmforall

Rich Murray, MA Room For All rmforall@...
1943 Otowi Road, Santa Fe, New Mexico 87505 USA 505-986-9103

http://groups.yahoo.com/group/aspartameNM/message/983
aspartame & formaldehyde toxicity: Murray 7.10.3 rmforall

http://groups.yahoo.com/group/aspartameNM/messages
for 1011 posts in a public searchable archive 118 members

http://groups.yahoo.com/group/aspartame/ 15494 posts 682 members

http://groups.yahoo.com/group/aspartameNM/message/989
EU votes 440 to 20 to approve sucralose, limit cyclamates & reevaluate
aspartame & stevia: Murray 4.12.3 rmforall

http://www.holisticmed.com/aspartame/scf2002-response.htm
Mark Gold exhaustively critiques European Commission Scientific
Committee on Food re aspartame (12.4.2): 59 pages, 230 references

http://groups.yahoo.com/group/aspartameNM/message/910
formaldehyde & formic acid from methanol in aspartame:
Murray: 12.9.2 rmforall

It is certain that high levels of aspartame use, above 2 liters daily
for months and years, must lead to chronic formaldehyde-formic acid
toxicity, since 11% of aspartame (1,120 mg in 2L diet soda, 5.6 12-oz
cans) is 123 mg methanol (wood alcohol), immediately released into the
body after drinking (unlike the large levels of methanol locked up in
molecules inside many fruits), then quickly transformed into
formaldehyde, which in turn becomes formic acid, both of which in
time are partially eliminated as carbon dioxide and water.

However, about 30% of the methanol remains in the body as cumulative
durable toxic metabolites of formaldehyde and formic acid-- 37 mg daily,
a gram every month. [J. Nutrition 1973 Oct; 103(10): 1454-1459.
Metabolism of aspartame in monkeys. Oppermann JA, Muldoon E, Ranney RE.]
If 10% of the methanol is retained as formaldehyde, that would give 12
mg daily formaldehyde accumulation, about 60 times more than the 0.2 mg
from 10% retention of the 2 mg EPA daily limit for formaldehyde in
drinking water.

Bear in mind that the EPA limit for formaldehyde in drinking water is
1 ppm, or 2 mg daily for a typical daily consumption of 2 L of water.

http://groups.yahoo.com/group/aspartameNM/message/835
RTM: ATSDR: EPA limit 1 ppm formaldehyde in drinking water July 1999
5.30.2 rmforall

This long-term low-level chronic toxic exposure leads to typical
patterns of increasingly severe complex symptoms, starting with
headache, fatigue, joint pain, irritability, memory loss, and
leading to vision and eye problems, and even seizures. In many cases
there is addiction. Probably there are immune system disorders, with a
hypersensitivity to these toxins and other chemicals.

Confirming evidence and a general theory are given by Pall (2002):
http://groups.yahoo.com/group/aspartameNM/message/909
testable theory of MCS type diseases, vicious cycle of nitric oxide &
peroxynitrite: MSG: formaldehyde-methanol-aspartame:
Martin L. Pall: Murray: 12.9.2 rmforall

http://groups.yahoo.com/group/aspartameNM/message/946
Functional Therapeutics in Neurodegenerative Disease Part 1/2:
Perlmutter 7.15.99: Murray 1.10.3 rmforall

http://google.com gives 149,000 websites for "aspartame" , with the top
9 listings being anti-aspartame, while
http://groups.google.com/ finds on 700 MB of posts from 20 years of
Usenet groups, 79,300 posts, the top 10 being anti-aspartame.
http://www.AllTheWeb.com gives 239,091, the top 5 being leading and
very well informed volunteer anti-aspartame sites.
http://teoma.com/index.asp gives 42,900 websites, the top 7 are anti.
http://www.ncbi.nlm.nih.gov/PubMed/ lists 734 aspartame items.

http://groups.yahoo.com/group/aspartameNM/message/915
formaldehyde toxicity: Thrasher & Kilburn: Shaham: EPA: Gold: Murray:
Wilson: CIIN: 12.12.2 rmforall

http://groups.yahoo.com/group/aspartameNM/message/934
24 recent formaldehyde toxicity [Comet assay] reports:
Murray 12.31.2 rmforall

http://groups.yahoo.com/group/aspartameNM/message/935
Comet assay finds DNA damage from sucralose, cyclamate, saccharin in
mice: Sasaki YF & Tsuda S Aug 2002: Murray 1.1.3 rmforall
[Also borderline evidence, in this pilot study of 39 food additives,
using a test group of 4 mice, for DNA damage from for stomach, colon,
liver, bladder, and lung 3 hr after oral dose of 2000 mg/kg aspartame--
a very high dose.]

http://groups.yahoo.com/group/aspartameNM/message/961
genotoxins, Comet assay in mice: Ace-K, stevia fine; aspartame poor;
sucralose, cyclamate, saccharin bad: Y.F. Sasaki Aug 2002:
Murray 1.27.3 rmforall [A detailed look at the data]

http://groups.yahoo.com/group/aspartameNM/message/939
aspartame (aspartic acid, phenylalanine) binding to DNA:
Karikas July 1998: Murray 1.5.3 rmforall
Karikas GA, Schulpis KH, Reclos GJ, Kokotos G
Measurement of molecular interaction of aspartame and
its metabolites with DNA. Clin Biochem 1998 Jul; 31(5): 405-7.
Dept. of Chemistry, University of Athens, Greece
http://www.chem.uoa.gr gkokotos@...

http://groups.yahoo.com/group/aspartameNM/message/960
aspartame & MSG: possible role in autoimmune hepatitis:
Prandota Jan 2003: Murray 1.15.3 rmforall

http://www.dorway.com/tldaddic.html 5-page review
Roberts HJ Aspartame (NutraSweet) addiction.
Townsend Letter 2000 Jan; HJRobertsMD@...
http://www.sunsentpress.com/ sunsentpress@...
Sunshine Sentinel Press P.O.Box 17799 West Palm Beach, FL 33416
800-814-9800 561-588-7628 561-547-8008 fax

http://groups.yahoo.com/group/aspartameNM/message/669
1038-page medical text "Aspartame Disease: An Ignored Epidemic"
published May 30 2001 $ 85.00 postpaid data from 1200 cases
available at http://www.amazon.com
over 600 references from standard medical research

Roberts, Hyman J., 1924- ,
Useful insights for diagnosis, treatment and public heath: an updated
anthology of original research, 2002, 798 pages,
Palm Beach Institute for Medical Research, Inc.
P.O. Box 17799, West Palm Beach, FL 33416
fax 561-547-8008 dr.roberts@...
aspartame disease pages 627-685, 778-780

http://groups.yahoo.com/group/aspartameNM/message/859
RTM: Roberts: the life work of a brilliant clinician:
aspartame toxicity 8.2.2 rmforall

http://groups.yahoo.com/group/aspartameNM/message/790
RTM: Moseley:
review Roberts "Aspartame Disease: An Ignored Epidemic" 2.7.2 rmforall

http://groups.yahoo.com/group/aspartameNM/message/782
RTM: Smith, Terpening, Schmidt, Gums:
full text: aspartame, MSG, fibromyalgia 1.17.2 rmforall
Jerry D Smith, Chris M Terpening, Siegfried OF Schmidt, and John G Gums
Relief of Fibromyalgia Symptoms Following
Discontinuation of Dietary Excitotoxins.
The Annals of Pharmacotherapy 2001; 35(6): 702–706.
Malcolm Randall Veterans Affairs Medical Center, Gainesville, FL, USA.
BACKGROUND: Fibromyalgia is a common rheumatologic disorder that is
often difficult to treat effectively.
CASE SUMMARY: Four patients diagnosed with fibromyalgia syndrome
for two to 17 years are described.
All had undergone multiple treatment
modalities with limited success. All had complete, or nearly complete,
resolution of their symptoms within months after eliminating monosodium
glutamate (MSG) or MSG plus aspartame from their diet.
All patients were women with multiple comorbidities
prior to elimination of MSG.
All have had recurrence of symptoms whenever MSG is ingested.

Siegfried O. Schmidt, MD Asst. Clinical Prof. siggy@...
Community Health and Family Medicine, U. Florida, Gainesville, FL
Shands Hospital
West Oak Clinic Gainesville, FL 32608-3629 352-376-5071

Debbie J. Hypes painfreeliving@... 304-872-4141 (Case # 1 of 4)
P.O Box 25 Lookout, WV 25868-0025 She has about 1,000 on her local
mailing list, and has been a volunteer activist since 1997. Her guide
first came out in 1997: http://www.Pain-Free-Living.net
"The Food Plan: How To Do It" $ 5 by mail, free by email.
Her sister Darlene, now 47, cured her own severe fibromyalgia in 1995
by using an elimination diet, and then Debbie also cured herself by
1997. Their doctor, Siegfried Schmidt, paying attention, tried it on
two more patients, who got well, and are his third and fourth cases.

http://groups.yahoo.com/group/aspartameNM/message/846
RTM: aspartame in Merck Maxalt-MLT worsens migraine,
AstraZeneca Zomig, Eli Lilly Zyprexa,
J&J Merck Pepcid AC (Famotidine 10mg) Chewable Tab,
Pfizer Cool Mint Listerine Pocketpaks 7.16.2 rmforall
Migraine MLT-Down: an unusual presentation of migraine
in patients with aspartame-triggered headaches.
Newman LC, Lipton RB Headache 2001 Oct; 41(9): 899-901.
[Merck 10-mg Maxalt-MLT, for migraine, has 3.75 mg aspartame,
while 12 oz diet soda has 200 mg.]
Headache Institute, St. Lukes-Roosevelt Hospital Center, New York, NY
Department of Neurology newmanache@...
Albert Einstein College of Medicine, Bronx, NY
Innovative Medical Research RLipton@...

http://groups.yahoo.com/group/aspartameNM/message/855
RTM: Blumenthall & Vance:
aspartame chewing gum headaches Nov 1997 7.28.2 rmforall
Harvey J. Blumenthal, MD, Dwight A Vance, RPh
Chewing Gum Headaches.
Headache 1997 Nov-Dec; 37(10): 665-6.
Department of Neurology, University of Oklahoma College of Medicine,
Tulsa, USA. neurotulsa@...
Aspartame, a popular dietetic sweetener, may provoke headache in some
susceptible individuals. Herein, we describe three cases of young women
with migraine who reported their headaches could be provoked by chewing
gum sweetened with aspartame. [6-8 mg aspartame per stick chewing gum]

http://groups.yahoo.com/group/aspartameNM/message/925
aspartame puts formaldehyde adducts into tissues, Part 1/2
full text, Trocho & Alemany 6.26.98: Murray 12.22.2 rmforall

http://groups.yahoo.com/group/aspartameNM/message/926
aspartame puts formaldehyde adducts into tissues, Part 2/2
full text, Trocho & Alemany 6.26.98: Murray 12.22.2 rmforall

http://ww.presidiotex.com/barcelona/index.html
Trocho C, Pardo R, Rafecas I, Virgili J, Remesar X,
Fernandez-Lopez JA, Alemany M ["Trok-ho"]
Formaldehyde derived from dietary aspartame binds to tissue
components in vivo. Life Sci 1998 Jun 26; 63(5): 337-49.
Departament de Bioquimica i Biologia Molecular, Facultat de Biologia,
Universitat de Barcelona, Spain.
http://www.presidiotex.com/barcelona/index.html
Maria Alemany, PhD (male) alemany@...

http://groups.yahoo.com/group/aspartameNM/message/864
Murray: Butchko, Tephly, McMartin: Alemany: aspartame formaldehyde
adducts in rats 9.8.2 rmforall
Prof. Alemany vigorously affirms the validity of the Trocho study
against criticism:
Butchko, HH et al [24 authors], Aspartame: review of safety.
Regul. Toxicol. Pharmacol. 2002 April 1; 35 (2 Pt 2): S1-93, review
available for $35, [an industry paid organ]. Butchko:
"When all the research on aspartame, including evaluations in both the
premarketing and postmarketing periods, is examined as a whole, it is
clear that aspartame is safe, and there are no unresolved questions
regarding its safety under conditions of intended use."
[They repeatedly pass on the ageless industry deceit that the methanol
in fruits and vegetables is as as biochemically available as that in
aspartame-- see the 1984 rebuttal by Monte, below.]

http://groups.yahoo.com/group/aspartameNM/message/911
RTP ties to industry criticized by CSPI: Murray: 12.9.2 rmforall
************************************************************************